O P E 47.08	1-7-06 ITM8	
AUG 0 4 2006 g INSTHE UNITED STATES P.	ATENT AND TRADEMARK OFFICE	
In re patent application of:)	
David A. WILLIAMS, et al.) Before the Examiner) Kelaginamane T. Hiriyanna	
Serial No. 10/705,561) Art Unit 1633	
Filed: November 11, 2005) Confirmation No. 5476	
METHODS FOR ENHANCED RETROVIRAL-MEDIATED GENE TRANSFER USING MOLECULES WITH VIRUS-AND CELL BINDING))))	
SUPPLEMENTAL INFORM	ATION DISCLOSURE STATEMENT	
MAIL STOP AMENDMENT Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450		
Sir:	•	
Pursuant to the provisions of 37 CFF	R 1.56, 1.97, and 1.98, Applicant requests	
consideration of the references listed on the	attached PTO/SB/08 forms and/or the additional	
information identified below.		
A legible copy of each foreign paten	t document and publication listed on the PTO/SB/08	
form is enclosed.		
	V747273142US, on the date indicated below.	180.00 OP
Ruth A. Rogers	Rubla Roger	18
Typed/printed name of person signing this certificate	Signature Signature	
Date	LR1 000	
	908	

Concise Explanation of Relevance for Non-English Language Information

For each the non-English language reference listed on the attached SB/08 forms, reference is made to a related patent publication (in the English language) cited herewith, as follows:

	Corresponding English Language
Foreign Patent Document	Patent Document
WO 97/18318	6,472,204 B1

This information Disclosure Statement is submitted after three months from the filing date and after the first Office Action on the merits, but prior to the mailing date of a final Office Action or Notice of Allowance, and thus a fee of \$180.00 (set forth in 37 CFR §1.17(p)) is enclosed. Should any other fee be required, please charge such fee to Deposit Account No. 23-3030, but not to include any payment of issue fees.

The filing of this Information Disclosure Statement shall not be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in §1.56(b).

Respectfully Submitted,

By:

John J. Emanuele, Jr.

Registration No. 51,653

Woodard, Emhardt, Moriarty,

McNett & Henry LLC

Bank One Center/Tower

111 Monument Circle, Suite 3700

Indianapolis, Indiana 46204-5137

(317) 634-3456

AUG 0 4 2006 W

WEMMH/SB/08A (4/03)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
TO COMMERCE
TO

Complete if Known Substitute for form 1449A/PTO 10/705,561 **Application Number** INFORMATION DISCLOSURE 11/11/2003 Filing Date STATEMENT BY APPLICANT David A. WILLIAMS First Named Inventor 1633 **Group Art Unit** (use as many sheets as necessary) **Examiner Name** Sheet of 1 **Attorney Docket Number** 7037-485 **U.S. PATENT DOCUMENTS** Publication Date Name of Patentee or Application Pages, Columns, Lines where Cite No.1 **Document Number** Examiner MM-DD-YYYY of Cited Document Relevant Passages or Relevant Number-Kind Code (if known) Initials' Figures Appear 6,472,204 **B**1 10-29-2002 Asada et al

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the emperor must precede the serial number of the patent document. 5 Kind of document by the apopropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.s. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A (09-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known 10/705,561 **Application Number** INFORMATION DISCLOSURE 11/11/2003 Filing Date STATEMENT BY APPLICANT David A. WILLIAMS First Named Inventor 1633 **Group Art Unit** (use as many sheets as necessary) **Examiner Name** 3 Sheet **Attorney Docket Number** 7037-485 **FOREIGN PATENT DOCUMENTS** Name of Patentee or Application of Cited Pages, Columns, Lines where Foreign Patent Document **Publication Date** Cite 1 Examiner Relevant Passages or Relevant MM-DD-YYYY Country Code-Number-Kind Code (if known) Initials' No. Figures Appear Document WO 97/18318 A1 05-22-1997 Takara Shuzo Co., L

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known					
INFORMATION DISCLOSURE				CLOSUPE	Application Number	10/705,561	
STATEMENT BY APPLICANT				Filing Date	11/11/2003		
O'ATEMENT BY ATTEMANT				LIOAIII	First Named Inventor	David A. WILLIAMS	
				Group Art Unit	1633		
(use as many sheets as necessary)		Examiner Name					
Sheet	3		of	3	Attorney Docket Number	7037-485	
		OTHER	PRIO	R ART - NON PA	TENT LITERATURE DO	CUMENTS	
Examiner Initials*	The state of the s				T ²		
					AL., "Gene therapy of Humase", Science, 2000, Vol./Iss		
	DHAWAN, SUBHASH ET AL, "Increased expression of alpha-4-beta-1 and alphta-5-beta-1 integrins on HTLV-I-infected lymphocytes", Virology, 1993, Vol./Issue No. 197:2, pp. 778-781						
	HANANBERG, H. ET AL, "Colocalization of Retrovirus and Target Cells on Specific Fibronectin Fragments Increases Genetic Transduction of Mammalian Cells", Nature Medicine, August 1996, Vol./Issue No. 2:8, pp. 876-882						
				FREY R. ET AL, "R Vol./Issue No. 10:4		inant Retroviruses", Biotechnology	
		retroviral	vector	AL., "Fibronectin ims: evidence of direction 88:3 pp. 855-	t viral binding to chymotryptic	nstituting hematopoietic stem cells by c carboxy-terminal fragments", Blood,	
		TRAYCC Mediated	LL, CN Gene	/I, ET AL., "The 30/3 Transfer (RMGT) in	35 kD Chymotryptic Fragmen	nt of Fibronectin Enhances Retrovial- emia (CML) CD34+ HLA-DR+ and L/Issue No. 22.8. pp. 934	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered, linclude copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.